Intravenous Alteplase compared to Tenecteplase in Acute Ischemic Stroke
Research Question

In patients with acute ischemic stroke eligible for intravenous thrombolysis, is tenecteplase non-inferior* to alteplase for 90-day excellent outcome (mRS 0-1) assessed using the modified Rankin Scale?

*Non-inferiority met if the lower 95% confidence interval of difference in primary outcome rates between tenecteplase vs. alteplase in intention-to-treat (ITT) analysis > -5%